| Similar Articles |
|---|
 |
Reason
October 2007
Ronald Bailey |
Is Industry-Funded Science Killing You? The overrated risks and underrated benefits of pharmaceutical research "conflicts of interest."   |
Bio-IT World
February 2006
Mark D. Uehling |
Pharma's Mixed Response to Trials Database A late December New England Journal of Medicine article detailed Big Pharma's response to mandatory registration of clinical trials. Here are some highlights. |
The Motley Fool
May 22, 2007
Mike Havrilla |
Avandia Safety Concerns Weigh Down Glaxo Shares of GlaxoSmithKline dropped nearly 8%, after a study raised safety concerns about the company's widely used diabetes drug, Avandia. |
BusinessWeek
October 23, 2006
Arlene Weintraub |
How The Journals Are Cracking Down With concerns about conflicts of interest on the rise, many medical journals are cracking down. |
Pharmaceutical Executive
June 1, 2005
Joanna Breitstein |
Turn the Page Changes in ethics and expectations are driving the way pharma interacts with medical publishers. |
Managed Care
July 2005
Martin Sipkoff |
Support Grows for Establishing National Clinical Trial Registry Stakeholders are pushing for a national clinical trial registry, and efforts by UnitedHealth Group are in the forefront. Medical journals are setting hard and fast rules. |
The Motley Fool
January 31, 2008
Brian Lawler |
Who Let the Docs Out? A leaked, confidential journal article could get Glaxo in hot water. |
Bio-IT World
July 2005
Kevin Davies |
Trial Registries on Trial A group of influential editors from some of the world's boutique medical journals begin enforcing a new policy that would bar drug companies from publishing clinical trial data unless those trials are registered in a suitable public database. |
Chemistry World
September 30, 2009
Matt Wilkinson |
Cox inhibitors stage a comeback Five years after the high-profile withdrawal of Merck & Co's arthritis drug Vioxx from the market, French pharmaceutical company NicOx is trying to wow the regulators with its first-in-class anti-inflammatory drug naproxcinod. |
BusinessWeek
July 30, 2007 |
Another Risk Factor For Merck Plaintiffs' lawyers are salivating over evidence they hope could support their argument that even patients who used the painkiller for short periods were in danger. |
Managed Care
September 2005
Arthur Lazarus |
Individual Wariness Needed To Spot Biased Drug Research Full and accurate disclosure of conflicts by researchers does not ensure the prevention of publication of articles that are misleading or otherwise biased. Impossible-to-enforce mandates won't work. Pharmacy directors and others must pose the right questions to the right people. |
Bio-IT World
December 15, 2004
Kevin Davies |
Patients Before Profits? After the Vioxx disaster, Pharma needs to reassure patients that they come first. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
December 13, 2005
Rich Duprey |
Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors. |
Chemistry World
May 22, 2007
Victoria Gill |
GSK Drug's Safety Questioned A prominent US clinician has concluded that a diabetes drug produced by UK pharmaceutical company GlaxoSmithKline increases the risks of heart attack and death. |
The Motley Fool
November 18, 2004
Lawrence Meyers |
Sympathy for Pfizer The market acts like Vioxx, Bextra, and Celebrex are the same drugs. They're not. Investors should change direction. |
The Motley Fool
April 4, 2007
Brian Lawler |
Novartis Gets Nicked Novartis pulls one of its top-selling drugs from the market. Investors should come to expect drug delays or similar issues popping up from time to time when doing their analysis of large pharmas. |
Information Today
October 4, 2004
Susanne Bjorner |
A Tough Test for PhRMA's New Clinical Study Results Database The announcement the day before of a worldwide withdrawal of Merck & Co.'s popular arthritis and acute pain medication Vioxx, created a high-bar test that shows the holes in the new database concept. |
Chemistry World
July 2007
Victoria Gill |
Conflict of interest? The FDA has been questioned after a published study brought exposed cardiovascular risks associated with GlaxoSmithKline's diabetes drug, Avandia. |
Information Today
March 5, 2012 |
Wiley-Blackwell Adds 44 Titles to Journal Publishing Program in 2012 Brand new titles publishing on Wiley Online Library over the course of 2012 include Advanced Healthcare Materials, PsyCH Journal, Clinical Liver Disease, Food and Energy Security and the open access title Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. |
BusinessWeek
December 13, 2004
Carol Marie Cropper |
The Inside Dope on Drugs Watchdog Web sites can tip you off to concerns that may not be on the label. Still, before you hit the Net, start with your doctor. And don't overlook the FDA's home page. |
Chemistry World
July 2007
Derek Lowe |
Opinion: In the Pipeline The Avandia controversy poses some tough questions about how to balance risks and showcases much broader implications for the pharmaceutical industry beyond this one drug. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
Information Today
October 15, 2012 |
ProQuest Continues to Upgrade Health and Medical Databases In addition to full-text integration of NEJM in its information products and a collection of classic images and deep index images, ProQuest will provide access to Journal Watch, the medical literature surveillance newsletter series. |
The Motley Fool
December 8, 2004
Alyce Lomax |
Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days. |
Information Today
January 26, 2009 |
Nature Publishing Group Expands Open Access Choices Nature Publishing Group is expanding open access choices for authors in 2009, through both "green" self-archiving and "gold" (authors-pays) open access publication routes. |
Salon.com
April 6, 2002
Eric Boehlert |
The Wall Street Journal's smear campaign The paper's Op-Ed pages have long been a platform for political assassination. But their latest target is a rival paper that is competing for a Pulitzer Prize... |
Information Today
March 2001
Paula J. Hane |
bepress.com Introduces Innovative Scholarly Publishing Model A new electronic publishing venture has launched that is taking on the scholarly publishing establishment. bepress.com (The Berkeley Electronic Press) was started by three University of California-Berkeley professors and a programmer from the Inktomi team... |
Information Today
February 16, 2012 |
Wolters Kluwer Health Expands Distribution Agreement With NEJM Under the terms of the agreement, Ovid will be the only medical research aggregator to distribute current, nonembargoed NEJM content to institutions and their clinicians, researchers, and students. |
Chemistry World
July 4, 2011
Andy Extance |
Funders Unveil 'Elite' Open Access Journal The Wellcome Trust, the Max Planck Society and the Howard Hughes Medical Institute are set to launch an open access research journal that will attempt to compete directly for submissions with Cell, Nature and Science. |
HHMI Bulletin
Aug 2011 |
HHMI Teams Up for Open Access Journal HHMI, the Max Planck Society, and the Wellcome Trust intend to launch an open-access journal for biomedical and life sciences research that breaks the mold set by traditional scientific journals. |
D-Lib
May/Jun 2007
Arthur Sale |
A Challenge for the Library Acquisition Budget Libraries have traditionally supported researchers as readers, but not as authors. It is desirable for the future of libraries, and for the future of research in their institutions, that libraries become engaged in this crucial step in the research process. |
The Motley Fool
December 12, 2007
Brian Orelli |
What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010. |
The Motley Fool
September 18, 2007
Brian Orelli |
Another Partnership for Personalized Medicine Celera gets a contract to design a companion diagnostic test for Merck. Investors, take note. |
Bio-IT World
June 2006
Kevin Davies |
The Data Deluge: Deal or No Deal? Far from decrying the data glut, researchers should embrace the complexity of genomic and other sources of data, particularly for its predictive properties in the field of personalized medicine. |
The Motley Fool
June 3, 2011
Brian Orelli |
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. |
D-Lib
Sep/Oct 2010
Changqing & Xiaodong |
Development Strategy for High-Quality Science and Technology Journals in China The Ministry of Science and Technology of China has planned and executed a development strategy for high-quality ST journals in order to advance the international competitive capacity of China's journals. |
The Motley Fool
February 23, 2005
Stephen D. Simpson |
Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector. |
The Motley Fool
September 30, 2004
W. D. Crotty |
Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment. |
The Motley Fool
August 22, 2005
Stephen D. Simpson |
Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares. |
Chemistry World
August 28, 2007
Lewis Brindley |
Mouse Study May Explain Vioxx Side-Effects Cell biologists may have discovered why the anti-inflammatory drug Vioxx and other Cox-2 inhibitors can cause life-threatening heart problems in some patients. |
The Motley Fool
April 11, 2007
Billy Fisher |
A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders. |
American Family Physician
October 15, 2003
Gavin et al. |
Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels. |
The Motley Fool
December 21, 2006
Brian Lawler |
Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout. |
HHMI Bulletin
Aug 2011
Robert Tjian |
President's Letter: Journal: Scientists at the Heart Journal aims to publish the highest-quality research across the full spectrum of the life sciences. |
BusinessWeek
November 29, 2004
Carey & Barrett |
Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do. |
The Motley Fool
March 1, 2006
Rich Duprey |
Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware. |
Managed Care
April 2006
Schmier et al. |
he Cost-Effectiveness of Omega-3 Supplements For Prevention of Secondary Coronary Events Dietary supplementation with omega-3 fatty acids in U.S. males is associated with fewer cardiovascular fatalities and lower costs |
Information Today
June 16, 2015 |
SAGE Announces Two New Journals SAGE Publications introduced Cardiovascular and Thoracic Open, an international, peer-reviewed, open access journal for surgeons and other medical professionals. |
The Motley Fool
April 10, 2006
Rich Duprey |
Merck Splits the Difference The pharmaceutical wins one, loses one in New Jersey Vioxx trials. Investors should expect to see more losses. |
